“…A limited number of preclinical studies have investigated the effects of SERMs on cognitive function and mood. For example, treatment with tamoxifen or raloxifene improved spatial working memory performance (Karahancer et al, 2008;Lagunas et al, 2011;Velazquez-Zamora et al, 2012), and raloxifene-treated OVX rats had reduced depressivelike (Karahancer et al, 2008) and anxiety-like behaviour (Walf and Frye, 2010). While clinical research investigating the therapeutic benefit of SERMs, particularly raloxifene, in schizophrenia has been and is continuing to be conducted (Wong et al, 2003;Kulkarni et al, 2010;Usall et al, 2011;Huerta-Ramos et al, 2014;Kianimehr et al, 2014), preclinical research is comparatively lacking and therefore the mechanism of action of these compounds remains unclear.…”